Welcome to the e-CCO Library!

P563: Comparison of long-term outcomes of infliximab with adalimumab in biologic naïve patients with Crohn’s disease: a tertiary referral center 13-year experience.
Year: 2021
Source: ECCO'21 Virtual
Authors: Yuksel, I.(1,2);Durak, M.B.(2);Kilic, V.(2);Kivrakoglu, F.(1,2);Kosar, K.(2);Erdogan, C.(2);Alkan, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P563: Monitoring of vedolizumab drug levels in a treat to target strategy for moderate-severe IBD (MOVE-IBD)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Logan, H.(1)*;Rimmer, K.(1);Doecke, J.(2);Patrick, D.(1);
Created: Friday, 14 July 2023, 11:05 AM
P563: Psychotherapy experience and demand for it and their association in inflammatory bowel disease – results from an internet-based survey
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Klag T.*1, Mazurak N.2, Fantasia L.1, Schwille-Kiuntke J.2, Kirschniak A.3, Goetz M.1, Malek N.1, Enck P.2, Wehkamp J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P563: Stopping anti-TNFα monotherapy in Crohn's disease patients in deep remission and favourable disease characteristics is associated with a high rate of relapse
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Soufleris1*, N. Kafalis1, K. Fasoulas1, G. Lazaraki1, I. Pilpilidis1, D. Tzilves1, O. Giouleme2

Created: Thursday, 21 February 2019, 9:14 AM
P563: Thiopurine adverse events in patients with inflammatory bowel disease in the UK: inflammatory bowel disease BioResource cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

Y. Y. Hong*1, D. A. Withanachchi1, S. P. Aslam1, Y. Khalid1, R. Shawky1, M. Parkes1

Created: Friday, 22 February 2019, 9:41 AM
P564 Psychological acceptance of surgery in patients with inflammatory bowel disease undergoing intestinal resection
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Hirano1,2, M. Itabashi3, T. Saito4, K. Uchida5, M. Inoue5, A. Katsuhiro2, H. Atsuhiro1, K. Araki1, Y. Nishikawa1, M. Tatsuno1, K. Hideaki1, K. Reiko1

Created: Thursday, 30 January 2020, 10:12 AM
P564: A qualitative exploration of acceptability of long-term use of oral nutritional supplement drinks as partial enteral nutrition in adolescent and adult Crohn's Disease
Year: 2022
Source: ECCO'22
Authors: Mu, S.(1);Wei, Y.(1);Weekes, E.(2);Keetarut, K.(2);
Created: Friday, 11 February 2022, 3:56 PM
P564: Indigo naturalis induces mucosal healing in patients with ulcerative colitis: A multicentre randomised controlled trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Naganuma1*, S. Sugimoto1, K. Mitsuyama2, T. Kobayashi3, N. Yoshimura4, H. Ohi5, K. Matsuoka6, T. Hisamatsu7, K. Watanabe8, T. Abe9, M. Watanabe6, T. Hibi3, Y. Suzuki10, T. Kanai1, INDIGO study group

Created: Thursday, 21 February 2019, 9:14 AM
P564: Low-dose azathioprine improves long-term efficacy of infliximab maintenance treatment in Japanese patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Nasuno M.*1, Motoya S.1, Sugiyama K.1, Miyakawa M.1, Tanaka H.1, Iida T.2, Onodera K.2, Nakase H.2

Created: Wednesday, 20 February 2019, 10:36 AM
P564: Significant reduction of admission time at the IBD infusion unit by an e-health pre-admission assessment and order system for intravenous therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Hoefkens*1, L. Pouillon1, V. Verheyen2, M. Bronswijk1, A. Van Olmen1, S. Van Dessel3, N. Siborgs4, P. Bossuyt1,5

Created: Friday, 22 February 2019, 9:41 AM
P564: Validation of the IBD-Disk instrument in a Portuguese cohort
Year: 2021
Source: ECCO'21 Virtual
Authors: Silva Mendes, S.(1,2);Ferreira, P.(2);Antunes, P.(1);Gonçalves, M.(1);Leal, T.(1);Gonçalves, B.(1);Rebelo, A.(1);Arroja, B.(1);Caetano, A.C.(1,2);Gonçalves, R.(1);Soares, J.B.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P564: vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease – a meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yiu, T.H.(1)*;Leong, R.(2);Ko, Y.(2);Pudipeddi, A.(2);
Created: Friday, 14 July 2023, 11:05 AM
P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B.E. Sands1, M.T. Abreu2, R.W.L. Leong3, C. Marano4, C.D. O’Brien4, H. Zhang5, Y. Zhou5, J. Johanns5, D. Rowbotham6, T. Hisamatsu7, R.P. Arasaradnam8, E. Scherl9, S. Danese10, L. Peyrin-Biroulet11, UNIFI Investigators

Created: Thursday, 30 January 2020, 10:12 AM
P565: Assessments of clinical efficacy and mucosal healing in ulcerative colitis patients undergoing granulomonocytapheresis at different treatment frequencies
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ohmori T., Ohmori S.

Created: Wednesday, 20 February 2019, 10:36 AM
P565: Comparison of the efficacy of adalimumab and ustekinumab for prevention of intestinal fibrosis in bio-naive Crohn's Disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Biscanin, A.(1,2)*;Tomašić, V.(1);Babic, F.(1);Ćaćić, P.(1);Ogresta Kordej, D.(1);Hrabar, D.(1,2);Kralj, D.(1);Dorosulić, Z.(1);
Created: Friday, 14 July 2023, 11:05 AM
P565: COVID-19 vaccination satisfaction and hesitancy in patients with inflammatory bowel disease: “inside referral center” survey
Year: 2022
Source: ECCO'22
Authors: Todeschini, A.(1);Contaldo, A.(1);Ierardi, E.(1);Di Leo, A.(1);Principi, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P565: Illness perception as a clinical tool to detect mood disturbances (anxiety or depression) in inflammatory bowel disease patients.
Year: 2021
Source: ECCO'21 Virtual
Authors: De Castro Parga, M.L.(1,2);Pereyra, D.(1);Sanromán, L.(1);Figueira, M.(1);Hernández, V.(1);Pineda, J.(1);Martinez-Cadilla, J.(1);Pereira, S.(1);Rodriguez-Prada, J.I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P565: Infliximab therapy intensification upon loss of response: what should be the cut-off for trough levels?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Ungar*1, Z. Ben-Shatach1, G. Ben-Haim1, M. Yavzori1, O. Picard1, E. Fudim1, U. Kopylov1, É. Del Tedesco2, P. Veyrard2, P. Stephane2, R. Eliaklim1, S. Ben-Horin1, X. Roblin2

Created: Friday, 22 February 2019, 9:41 AM
P565: Real-world use of azathioprine metabolites changes clinical management of inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Tuson1, L. Wilson1, L. Yang2,3, D. Loomes1,3*

Created: Thursday, 21 February 2019, 9:14 AM
P566 Assessing the efficacy of biologics in ulcerative colitis: A real-life, observational retrospective multicenter study using the propensity score analysis: The ‘A.U.R.O.R.A.’ comparison study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Cassinotti1, N. Mezzina1, D. Di Paolo2, M.V. Lenti3, C. Bezzio4, D. Stradella5, M. Mauri6, V. Zadro1, C. Cortellezzi7, C. Ricci8, V. Casini9, E. Radice10, A. Massari1, S. Ardizzone1, L. Pastorelli2, A. Di Sabatino3, G. Manes4, F. Caprioli11, M. Vecchi11, R. Tari5, P. Occhipinti5, M. Fichera6, P. Invernizzi6, M. Parravicini7, S. Segato7, F. Pace9, P.A. Testoni10, C. Tinelli12, A. De Silvestri12

Created: Thursday, 30 January 2020, 10:12 AM